18F-FDG PET/CT与增强CT联合血清CA 19-9检测复发性胰腺腺癌的效用
回顾性分析39例胰腺腺癌术后随访或临床怀疑复发患者,PET/CT诊断复发的敏感度90.9%、特异度100.0%、准确率92.3%,CECT分别为72.2%、66.6%、71.7%;PET/CT在12例CA 19-9正常患者中检出复发,并在5例(15%)中显示CECT未见病灶。
要点
- PET/CT诊断复发的敏感度90.9%、特异度100.0%,CECT分别为72.2%、66.6%。
- PET/CT在12例血清CA 19-9正常患者中检出复发。
- PET/CT在5例(15%)中显示CECT未见的病灶。
核心结论
- FDG PET/CT对胰腺癌复发具有高敏感度,CA 19-9正常不能排除复发,PET/CT在CECT结果不明确时有用,并可在CA 19-9正常患者中检出复发。
研究设计与样本
- 回顾性研究,纳入39例胰腺腺癌术后随访或临床怀疑复发的患者,两名观察者在对另一种影像结果设盲的情况下共识判读,采用三点量表(阴性、可疑、阳性),以活检病理或进一步临床和影像随访确定真实复发状态。
诊断标准与关键数值
- PET/CT诊断复发的敏感度90.9%、特异度100.0%、准确率92.3%;CECT分别为72.2%、66.6%、71.7%;局部区域复发敏感度PET/CT 94.4%、CECT 61.1%;PET/CT与CECT敏感度和特异度差异无统计学意义(p=0.489和p=0.1489)。
临床应用与阅片要点
- 作者认为FDG PET/CT在CECT结果不明确时有用,并可检出CA 19-9正常患者的复发。
局限性
- PET/CT与CECT的敏感度和特异度差异未达统计学显著(p=0.489和p=0.1489)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The roles of different cross-sectional imaging in evaluating the recurrence of pancreatic adenocarcinoma are not well established. We evaluated the utility of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and contrast-enhanced computed tomography (CECT) in the diagnosis of recurrent pancreatic adenocarcinoma in conjunction with the tumor marker CA 19-9.
METHODS: We retrospectively reviewed the records of patients who underwent CECT and FDG PET/CT along with serum CA 19-9 measurement as a follow-up or on a clinical suspicion of recurrent disease after initial surgery for pancreatic adenocarcinoma. Two observers blinded to the other imaging modality results retrospectively reviewed and interpreted the images in consensus using a three-point scale (negative, equivocal, or positive). Pathologic analysis by biopsy or further clinical and radiologic follow-up determined the true status of the suspected recurrences. The imaging results were compared with CA 19-9 levels and true disease status.
RESULTS: Thirty-nine patients were included in the study. Thirty-three patients (85%) had proven recurrent cancer and six patients (15%) had no evidence of disease. Twenty-four patients had elevated CA 19-9 and 15 patients had normal CA 19-9. Sensitivity, specificity, and accuracy for recurrence were 90.9%, 100.0%, and 92.3% for PET/CT and 72.2%, 66.6%, and 71.7% for CECT, respectively. Sensitivity for locoregional recurrence was 94.4% for PET/CT but only 61.1% for CECT. PET/CT detected recurrence in 12 patients who had normal levels of CA 19-9. PET/CT showed lesions not visible on CECT in five (15%) patients. Although the sensitivity and specificity of PET/CT were higher than those of CECT, they were not statistically significant (p = 0.489 and p = 0.1489, respectively).
CONCLUSION: FDG PET/CT has a high sensitivity for pancreatic cancer recurrence. Normal CA 19-9 does not necessarily exclude these recurrences. FDG PET/CT is useful when CECT is equivocal and can detect recurrence in patients with normal CA 19-9.
引用
- Rayamajhi S, Balachandran A, Katz M, et al. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma. Abdom Radiol (NY). 2018. PMID: 28900703. doi:10.1007/s00261-017-1316-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。